this page is secure
Anti-Obesity Effect of Lactoferrin; Subgroup Analysis Excluding Subjects with Obese and/or Hyper-LDL Cholesterolemia
Background: Lactoferrin is a multifunctional protein found in breast milk. We previously reported the anti-obesity effects of enteric-coated lactoferrin (eLF).
Objective: As the previous study included some subjects with high Body Mass Index (BMI) or low-Density Lipoprotein cholesterol (LDL-Cho), we investigated the antiobesity effect of lactoferrin excluding those subjects.
Method: We conducted a subgroup analysis of a previous report excluding subjects with BMI ≥ 30 and/or hyper-LDL cholesterolemia.
Results: Of the total 26 subjects in the previous study, 7 in the eLF group and 6 in the placebo group match the above criteria. The subgroup analysis revealed a significant decrease in visceral fat in the eLF group at week 8 compared with that at week 0 (-10.2 cm2, P < 0.01); no differences were observed in the placebo group. The mean visceral fat was also lower in the eLF group at week 8 compared with the placebo group (-16.2 cm2, P < 0.01). A significant decrease in BMI was observed in the eLF group at week 8 (-0.38 kg/m2, P < 0.05) compared with that at week 0. No differences were observed in the placebo group. The mean BMI was also lower in the eLF group at week 8 compared with that in the placebo group (-0.60 kg/m2, P < 0.05).
Conclusion: eLF reduced visceral fat and BMI excluding subjects with obese and/or hyper- LDL cholesterolemia.
Objective: As the previous study included some subjects with high Body Mass Index (BMI) or low-Density Lipoprotein cholesterol (LDL-Cho), we investigated the antiobesity effect of lactoferrin excluding those subjects.
Method: We conducted a subgroup analysis of a previous report excluding subjects with BMI ≥ 30 and/or hyper-LDL cholesterolemia.
Results: Of the total 26 subjects in the previous study, 7 in the eLF group and 6 in the placebo group match the above criteria. The subgroup analysis revealed a significant decrease in visceral fat in the eLF group at week 8 compared with that at week 0 (-10.2 cm2, P < 0.01); no differences were observed in the placebo group. The mean visceral fat was also lower in the eLF group at week 8 compared with the placebo group (-16.2 cm2, P < 0.01). A significant decrease in BMI was observed in the eLF group at week 8 (-0.38 kg/m2, P < 0.05) compared with that at week 0. No differences were observed in the placebo group. The mean BMI was also lower in the eLF group at week 8 compared with that in the placebo group (-0.60 kg/m2, P < 0.05).
Conclusion: eLF reduced visceral fat and BMI excluding subjects with obese and/or hyper- LDL cholesterolemia.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics
Keywords: BMI; Lactoferrin; RCT trial; enteric-coated; subgroup analysis; visceral fat
Document Type: Research Article
Publication date: May 1, 2018
- Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in the medicinal chemistry and rational drug design for the discovery of new Immunology, Endocrine & Metabolic Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Immunology, Endocrine & Metabolic medicinal chemistry.
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Immunology, Endocrine & Metabolic drug discovery. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert